A team of British researchers is testing a new vaccine against prostate, lung and ovarian cancer. The immunizer is used for volunteers and was developed by Oxford Vacmedix, a company set up by researchers at the University of Oxford in the UK.
The product targets a survivin protein that is released by cancer cells to bypass the immune system and prevent attacks on the body. In the synthetic version of the protein, the vaccine is designed to train the body to attack the substance and also to recognize tumors.
A total of 35 cancer patients volunteered to receive three doses of the vaccine every two weeks. They will all be monitored for six months after the submission of applications.
According to experts, the preliminary results look promising. On the other hand, the group calls for caution, as volunteers need to be monitored over time to analyze the possible side effects of the vaccine and determine its impact on the survival of the participants.
Source: The Globe
Have you watched the new videos? YouTube about a digital look? Order the channel!